Michael Krams, M.D., Joins Exscientia as Chief Quantitative Medicine Officer
5.4.2022 15:00:00 EEST | Business Wire | Press release
Exscientia plc (Nasdaq: EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer. In this newly created role, Dr. Krams will lead clinical development strategy for Exscientia’s portfolio of investigational medicines. Exscientia’s drug discovery platform utilises patient-based translational models and AI-driven molecule design to optimise drug candidates for specific patient populations. As part of these efforts, Dr. Krams will drive work to improve trial design and patient selection within clinical trials to maximise clinical success and patient benefit.
“We want to be as innovative in the clinic as we have been in drug discovery. Mike is a proven innovator and strategic leader at the vanguard of bringing a quantitative science approach to clinical development. He has been a thought leader in the field for more than 20 years, implementing model-informed drug development, increasing the use of biomarkers to enable adaptive trials, and finding better ways to enrich trials for patient selection,” said Andrew Hopkins, DPhil., Exscientia’s founder and CEO. “Focusing our clinical trials on the people that are most likely to benefit from them has the potential to not only improve clinical success rates, but it also advances our mission of putting patients at the centre of creating new medicines.”
Dr. Krams joins Exscientia’s executive leadership team, reporting to Andrew Hopkins, and will be based at Exscientia’s precision medicine centre in Vienna, Austria. Dr. Krams most recently led the Quantitative Sciences group at Janssen R&D, bringing together approximately 500 statisticians, pharmacologists and modellers to enable efficient decision-making in various aspects of drug development. Earlier in his career, he was Vice President of Adaptive Trials and Applied Program Strategies at Wyeth. Dr. Krams holds an M.D. from the University of Munich.
“I’m pleased to join Exscientia, a mission-driven company harnessing artificial intelligence to transform drug discovery and development to make better medicines for patients. In many ways, the work I’ve driven throughout my career is a good match to Exscientia’s goal - asking how conventional, sequential approaches to clinical development can be further improved, aiming for truly patient-driven medicine development. Discovery and clinical strategies need to be closely connected through biomarker strategies and Exscientia’s precision medicine platform has the potential to achieve just that,” said Mike Krams, M.D., Chief Quantitative Medicine Officer for Exscientia.
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 30 projects underway. By designing better drugs, faster, we believe the best ideas of science can rapidly become the best medicines for patients.
Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).
Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements with regard to Exscientia’s expectations regarding its management team. Words such as “anticipates,” "believes," “expects,” "intends," "projects," "anticipates," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the uncertainties inherent in predicting future results and conditions and no assurance can be given that the drug discovery and precision medicine platforms discussed above will be successful in optimising drug candidates for specific patient populations. The success of Exscientia’s platforms is subject to numerous factors, many of which are beyond the control of Exscientia, including, without limitation, the ability of Exscientia to design clinical trials that are cleared by the FDA and of healthcare providers to collect viable patient tissue samples. Exscientia undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005276/en/
Contact information
Investors:
Sara Sherman
investors@exscientia.ai
Media:
Amanda Galgay
media@exscientia.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Premier Jumping League (PJL) & McCarthy Jumping Team Announce Landmark Purchase29.6.2026 16:10:00 EEST | Press release
The Premier Jumping League (PJL) today announced that seasoned trader, investor, and competitive race car driver Jason McCarthy and McCarthy Jumping League LLC acquired the first PJL team in a landmark $50 million acquisition, building on rising momentum for the highly acclaimed professional jumping league. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629512997/en/ The Premier Jumping League (PJL), photographed by Daniel Benson. The milestone investment represents an unprecedented valuation for a team in a newly established sports competition and underscores the confidence that sophisticated investors are placing in the PJL. The inaugural PJL season is scheduled to commence in April 2027. McCarthy brings extensive investment and trading experience to the League, having held leadership positions across the financial sector throughout his career. A graduate of MIT, McCarthy is the Founder and Managing Principal of a propr
InvestEco Sustainable Food Fund IV Holds a Final Close With Total Commitments of C$106M29.6.2026 16:00:00 EEST | Press release
InvestEco Capital is pleased to announce the final close of the InvestEco Sustainable Food Fund IV. This fund will continue InvestEco’s work of investing in high-growth food companies that promote health and sustainability in the food sector. The Fund closed with total commitments of C$106M, the largest InvestEco fund to date. Investors include Farm Credit Canada, Export Development Canada, Business Development Bank of Canada, Fonds de solidarité FTQ, and two Government of Canada Social Finance Fund wholesalers: Boann and Realize Capital Partners. In addition, the Fund received commitments from a number of private investors and family offices. The Fund's investments to date include Humble Snacks, Little Sesame, Mid-Day Squares and Algae Cooking Club. The Fund expects to make a further 6 - 10 investments over the next few years. InvestEco Capital, founded in 2002, is a Toronto-based venture capital firm and impact investor focused on the sustainable food sector. For more information, em
Geoswift and SKUx Announce Strategic Partnership to Develop a First-of-Its-Kind Programmable Stablecoin Commerce Network29.6.2026 15:00:00 EEST | Press release
Geoswift and SKUx announced a groundbreaking partnership to develop a next-generation programmable stablecoin commerce network. This strategic collaboration bridges digital assets, traditional finance, and real-world commerce at a global scale, representing a "one-of-one" opportunity by combining Geoswift's global infrastructure with SKUx's specialized item-level controls directly within point-of-sale (POS) systems. While enterprise stablecoin usage continues to accelerate globally, governments, enterprises, payment networks, and AI-driven commerce platforms are increasingly seeking programmable payment infrastructure that can bridge digital assets with real-world commerce. The innovation goes far beyond treasury management or even enabling consumers to spend stablecoins at retail locations. Instead, it unlocks true "programmable money" with embedded controls, rules, and purpose-driven utility —requiring both programmable settlement and programmable spending controls. Geoswift and SKUx
Esri Sponsors Smithsonian Exhibition Showcasing Natural and Cultural Objects from All 50 States29.6.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, is sponsoring From These Lands: Sharing Our Natural and Cultural Heritage, a new exhibition at the Smithsonian's National Museum of Natural History that showcases objects from all 50 states and explores the deep connections between people, place, and the natural world that unite the nation. The exhibit, which opened this June 18 and runs through 2029, brings together more than 600 specimens and cultural artifacts from across the United States, Washington, DC, and the five territories that people call home. Drawing from the museum's own collection, From These Lands shows how natural systems, cultural traditions, and geography intersect. The exhibition presents stories that span millions of years—from ancient fossils and geological formations to cultural artifacts and scientific breakthroughs—inviting visitors to reflect on their own sense of place. By pairing natural specimens with cultural objects, From These Lands demonstrates how huma
Cartilage Tissue Engineering Heads to Orbit in NSF and NASA-supported Study at the International Space Station29.6.2026 15:00:00 EEST | Press release
Researchers in the DELTAi Lab at the University of California, Irvine, working with NASA, are using Evercode Cell Fixation to preserve samples aboard the International Space Station as part of a study of cartilage tissue engineering in microgravity. The unprecedented work, part of a National Science Foundation (NSF)-funded grant led by Dr. Wendy Brown and Dr. Kyriacos Athanasiou, announced today by Parse Biosciences, aims to advance treatments for the hundreds of millions of people worldwide affected by cartilage injury. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629548658/en/ Rachel Nordberg, PhD, from the DELTAi Lab at UC Irvine, prepping the BioServe device before it goes into orbit. Cartilage injuries cause significant pain and disability, and the need for implants that can repair or regenerate damaged tissue without harming a donor site has gone unmet for decades. Part of the difficulty is gravity itself, which m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom